Development of A Novel In Vitro Human Tissue-Based Angiogenesis Assay to Evaluate the Effect of Antiangiogenic Drugs

Eugene A. Woltering, James Lewis, P. Johnstone Maxwell IV, Daniel J. Frey, Yi Zarn Wang, John Rothermel, Catherine T. Anthony, Douglas A. Balster, J. Patrick O'Leary, Lynn H. Harrison, James C. Thompson, C. Wright Pinson, Samuel W. Beenken, Eugene A. Woltering

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: To describe a novel in vitro human tissue-based angiogenic model that can predict an individual tumor'; s response to antiangiogenic drugs. Summary Background Data: A number of in vitro and in vivo angiogenesis assays exist, but they do not provide potentially useful information for the treatment of an individual patient. Clonogenic assays have been used to evaluate the response of an individual'; s tumor to antineoplastic agents, but these tumor fragments are cultured in an environment that does not lead to neovessel growth. The authors have previously demonstrated that human vein disks or human tumor xenograft fragments incorporated into a 0.3% fibrin-thrombin clot will develop angiogenic vessel growth from the cut edge of the vessel disk or xenograft fragment. Methods: Fresh human tumor or normal tissue disks (2 × 1 mm) from fresh surgical specimens were incorporated into fibrin-thrombin clots overlain with nutrient medium containing either 20% fetal bovine serum alone or in combination with Epothilone B, a tubulin inhibitor with antiangiogenic properties. Tissue disks were visually assessed over time to determine the percentage of wells that developed an angiogenic response. Neovessel growth, density, and length were graded at intervals using a semiquantitative visual neovessel growth-rating scheme (angiogenic index, 0-16 scale) devised in the authors'; laboratory. Results: Epothilone B treatment at doses of 10 -5 mol/L and 10-8 mol/L decreased the number of wells that developed an invasive angiogenic response and limited the development of vessels that invaded the matrix. At these doses, Epothilone B also caused regression of vessels in wells that had been allowed to develop an angiogenic response. Treatment of tumors or normal tissues with Epothilone 13 at doses less than 10-8 mol/L was ineffective. Conclusions: Epothilone B may be an effective antiangiogenic agent in a variety of tumor types. The authors speculate that this in vitro model might provide useful information to the clinician on the effect of specific antiangiogenic agents on individual tumors. This may be particularly useful in patients with tumors that, as a group, are unresponsive to treatment with antineoplastic agents.

Original languageEnglish (US)
Pages (from-to)790-800
Number of pages11
JournalAnnals of surgery
Volume237
Issue number6
DOIs
StatePublished - Jan 1 2003

Fingerprint

Pharmaceutical Preparations
Neoplasms
Angiogenesis Inhibitors
Growth
Fibrin
Heterografts
Thrombin
Antineoplastic Agents
Tubulin Modulators
Epothilones
In Vitro Techniques
Therapeutics
Veins
Food
epothilone B
Serum

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Development of A Novel In Vitro Human Tissue-Based Angiogenesis Assay to Evaluate the Effect of Antiangiogenic Drugs. / Woltering, Eugene A.; Lewis, James; Maxwell IV, P. Johnstone; Frey, Daniel J.; Wang, Yi Zarn; Rothermel, John; Anthony, Catherine T.; Balster, Douglas A.; O'Leary, J. Patrick; Harrison, Lynn H.; Thompson, James C.; Pinson, C. Wright; Beenken, Samuel W.; Woltering, Eugene A.

In: Annals of surgery, Vol. 237, No. 6, 01.01.2003, p. 790-800.

Research output: Contribution to journalArticle

Woltering, EA, Lewis, J, Maxwell IV, PJ, Frey, DJ, Wang, YZ, Rothermel, J, Anthony, CT, Balster, DA, O'Leary, JP, Harrison, LH, Thompson, JC, Pinson, CW, Beenken, SW & Woltering, EA 2003, 'Development of A Novel In Vitro Human Tissue-Based Angiogenesis Assay to Evaluate the Effect of Antiangiogenic Drugs', Annals of surgery, vol. 237, no. 6, pp. 790-800. https://doi.org/10.1097/01.SLA.0000072111.53797.44
Woltering, Eugene A. ; Lewis, James ; Maxwell IV, P. Johnstone ; Frey, Daniel J. ; Wang, Yi Zarn ; Rothermel, John ; Anthony, Catherine T. ; Balster, Douglas A. ; O'Leary, J. Patrick ; Harrison, Lynn H. ; Thompson, James C. ; Pinson, C. Wright ; Beenken, Samuel W. ; Woltering, Eugene A. / Development of A Novel In Vitro Human Tissue-Based Angiogenesis Assay to Evaluate the Effect of Antiangiogenic Drugs. In: Annals of surgery. 2003 ; Vol. 237, No. 6. pp. 790-800.
@article{b25306f6b06748598e8b2d38b971485f,
title = "Development of A Novel In Vitro Human Tissue-Based Angiogenesis Assay to Evaluate the Effect of Antiangiogenic Drugs",
abstract = "Objective: To describe a novel in vitro human tissue-based angiogenic model that can predict an individual tumor'; s response to antiangiogenic drugs. Summary Background Data: A number of in vitro and in vivo angiogenesis assays exist, but they do not provide potentially useful information for the treatment of an individual patient. Clonogenic assays have been used to evaluate the response of an individual'; s tumor to antineoplastic agents, but these tumor fragments are cultured in an environment that does not lead to neovessel growth. The authors have previously demonstrated that human vein disks or human tumor xenograft fragments incorporated into a 0.3{\%} fibrin-thrombin clot will develop angiogenic vessel growth from the cut edge of the vessel disk or xenograft fragment. Methods: Fresh human tumor or normal tissue disks (2 × 1 mm) from fresh surgical specimens were incorporated into fibrin-thrombin clots overlain with nutrient medium containing either 20{\%} fetal bovine serum alone or in combination with Epothilone B, a tubulin inhibitor with antiangiogenic properties. Tissue disks were visually assessed over time to determine the percentage of wells that developed an angiogenic response. Neovessel growth, density, and length were graded at intervals using a semiquantitative visual neovessel growth-rating scheme (angiogenic index, 0-16 scale) devised in the authors'; laboratory. Results: Epothilone B treatment at doses of 10 -5 mol/L and 10-8 mol/L decreased the number of wells that developed an invasive angiogenic response and limited the development of vessels that invaded the matrix. At these doses, Epothilone B also caused regression of vessels in wells that had been allowed to develop an angiogenic response. Treatment of tumors or normal tissues with Epothilone 13 at doses less than 10-8 mol/L was ineffective. Conclusions: Epothilone B may be an effective antiangiogenic agent in a variety of tumor types. The authors speculate that this in vitro model might provide useful information to the clinician on the effect of specific antiangiogenic agents on individual tumors. This may be particularly useful in patients with tumors that, as a group, are unresponsive to treatment with antineoplastic agents.",
author = "Woltering, {Eugene A.} and James Lewis and {Maxwell IV}, {P. Johnstone} and Frey, {Daniel J.} and Wang, {Yi Zarn} and John Rothermel and Anthony, {Catherine T.} and Balster, {Douglas A.} and O'Leary, {J. Patrick} and Harrison, {Lynn H.} and Thompson, {James C.} and Pinson, {C. Wright} and Beenken, {Samuel W.} and Woltering, {Eugene A.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1097/01.SLA.0000072111.53797.44",
language = "English (US)",
volume = "237",
pages = "790--800",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Development of A Novel In Vitro Human Tissue-Based Angiogenesis Assay to Evaluate the Effect of Antiangiogenic Drugs

AU - Woltering, Eugene A.

AU - Lewis, James

AU - Maxwell IV, P. Johnstone

AU - Frey, Daniel J.

AU - Wang, Yi Zarn

AU - Rothermel, John

AU - Anthony, Catherine T.

AU - Balster, Douglas A.

AU - O'Leary, J. Patrick

AU - Harrison, Lynn H.

AU - Thompson, James C.

AU - Pinson, C. Wright

AU - Beenken, Samuel W.

AU - Woltering, Eugene A.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Objective: To describe a novel in vitro human tissue-based angiogenic model that can predict an individual tumor'; s response to antiangiogenic drugs. Summary Background Data: A number of in vitro and in vivo angiogenesis assays exist, but they do not provide potentially useful information for the treatment of an individual patient. Clonogenic assays have been used to evaluate the response of an individual'; s tumor to antineoplastic agents, but these tumor fragments are cultured in an environment that does not lead to neovessel growth. The authors have previously demonstrated that human vein disks or human tumor xenograft fragments incorporated into a 0.3% fibrin-thrombin clot will develop angiogenic vessel growth from the cut edge of the vessel disk or xenograft fragment. Methods: Fresh human tumor or normal tissue disks (2 × 1 mm) from fresh surgical specimens were incorporated into fibrin-thrombin clots overlain with nutrient medium containing either 20% fetal bovine serum alone or in combination with Epothilone B, a tubulin inhibitor with antiangiogenic properties. Tissue disks were visually assessed over time to determine the percentage of wells that developed an angiogenic response. Neovessel growth, density, and length were graded at intervals using a semiquantitative visual neovessel growth-rating scheme (angiogenic index, 0-16 scale) devised in the authors'; laboratory. Results: Epothilone B treatment at doses of 10 -5 mol/L and 10-8 mol/L decreased the number of wells that developed an invasive angiogenic response and limited the development of vessels that invaded the matrix. At these doses, Epothilone B also caused regression of vessels in wells that had been allowed to develop an angiogenic response. Treatment of tumors or normal tissues with Epothilone 13 at doses less than 10-8 mol/L was ineffective. Conclusions: Epothilone B may be an effective antiangiogenic agent in a variety of tumor types. The authors speculate that this in vitro model might provide useful information to the clinician on the effect of specific antiangiogenic agents on individual tumors. This may be particularly useful in patients with tumors that, as a group, are unresponsive to treatment with antineoplastic agents.

AB - Objective: To describe a novel in vitro human tissue-based angiogenic model that can predict an individual tumor'; s response to antiangiogenic drugs. Summary Background Data: A number of in vitro and in vivo angiogenesis assays exist, but they do not provide potentially useful information for the treatment of an individual patient. Clonogenic assays have been used to evaluate the response of an individual'; s tumor to antineoplastic agents, but these tumor fragments are cultured in an environment that does not lead to neovessel growth. The authors have previously demonstrated that human vein disks or human tumor xenograft fragments incorporated into a 0.3% fibrin-thrombin clot will develop angiogenic vessel growth from the cut edge of the vessel disk or xenograft fragment. Methods: Fresh human tumor or normal tissue disks (2 × 1 mm) from fresh surgical specimens were incorporated into fibrin-thrombin clots overlain with nutrient medium containing either 20% fetal bovine serum alone or in combination with Epothilone B, a tubulin inhibitor with antiangiogenic properties. Tissue disks were visually assessed over time to determine the percentage of wells that developed an angiogenic response. Neovessel growth, density, and length were graded at intervals using a semiquantitative visual neovessel growth-rating scheme (angiogenic index, 0-16 scale) devised in the authors'; laboratory. Results: Epothilone B treatment at doses of 10 -5 mol/L and 10-8 mol/L decreased the number of wells that developed an invasive angiogenic response and limited the development of vessels that invaded the matrix. At these doses, Epothilone B also caused regression of vessels in wells that had been allowed to develop an angiogenic response. Treatment of tumors or normal tissues with Epothilone 13 at doses less than 10-8 mol/L was ineffective. Conclusions: Epothilone B may be an effective antiangiogenic agent in a variety of tumor types. The authors speculate that this in vitro model might provide useful information to the clinician on the effect of specific antiangiogenic agents on individual tumors. This may be particularly useful in patients with tumors that, as a group, are unresponsive to treatment with antineoplastic agents.

UR - http://www.scopus.com/inward/record.url?scp=85047690366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047690366&partnerID=8YFLogxK

U2 - 10.1097/01.SLA.0000072111.53797.44

DO - 10.1097/01.SLA.0000072111.53797.44

M3 - Article

C2 - 12796575

AN - SCOPUS:85047690366

VL - 237

SP - 790

EP - 800

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 6

ER -